EMPAGREAT 10 TAB

About

Empagliflozin is an SGLT2 inhibitor prescribed for the management of type 2 diabetes mellitus. Its primary mechanism involves inhibiting the sodium-glucose co-transporter 2 in the renal tubules, which reduces glucose reabsorption and increases glucose excretion in the urine. This leads to a reduction in blood glucose levels, a modest decrease in body weight, and a reduction in blood pressure. Empagliflozin has been extensively studied and has demonstrated significant benefits beyond glycemic control, including a reduction in the risk of cardiovascular death, hospitalization for heart failure, and progression of kidney disease in patients with type 2 diabetes and established cardiovascular disease or chronic kidney disease. It is an important therapeutic option for comprehensive diabetes management.

Uses

• Treatment of type 2 diabetes mellitus.
• Reduction of risk of cardiovascular death.
• Reduction of risk of hospitalization for heart failure.
• Improvement of glycemic control.

Directions For Use

Take empagliflozin orally once daily in the morning, with or without food, as directed by your healthcare provider.

Benefits

• Effectively lowers blood glucose and HbA1c.
• Promotes weight loss.
• Reduces blood pressure.
• Proven cardiovascular mortality reduction.
• Reduces risk of heart failure hospitalization.
• Provides renal protection.

Side Effects

• Genital mycotic infections
• Urinary tract infections
• Increased urination
• Thirst
• Dizziness
• Hypotension
• Diabetic ketoacidosis (rare)
• Kidney impairment (rare)
• Back pain
• Nausea
• Fatigue
• Flu-like symptoms

Safety Measures

• Alcohol - Excessive alcohol intake may increase the risk of dehydration and ketoacidosis. Use with caution.
• Pregnancy - Not recommended during the second and third trimesters of pregnancy due to potential adverse effects on kidney development.
• Breastfeeding - Not recommended during breastfeeding as it is unknown if empagliflozin is excreted in human milk.
• Liver - No dose adjustment is generally needed for mild to moderate liver impairment. Use with caution in severe impairment.
• Kidney - Not recommended for patients with severe kidney impairment (eGFR <20 mL/min/1.73m²) for glycemic control.
• Lung - Generally safe for use in patients with lung conditions; no specific contraindications related to pulmonary function.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.